Demonstration of Human T Lymphotropic Virus Type I (HTLV-I)-Specific T Cell Responses from Seronegative and Polymerase Chain Reaction-Negative Persons Exposed to HTLV-I

M. Nishimura; A.G. Kermode; M. Clerici; G.M. Shearer; J.A. Berzofsky; T. Uchiyama; S.Z. Wiktor; E. Pate; B. Maloney; A. Manns; W. Blattner; S. Jacobson

doi:10.1093/infdis/170.2.334

Back

Demonstration of Human T Lymphotropic Virus Type I (HTLV-I)-Specific T Cell Responses from Seronegative and Polymerase Chain Reaction-Negative Persons Exposed to HTLV-I

Journal article

Peer reviewed

Demonstration of Human T Lymphotropic Virus Type I (HTLV-I)-Specific T Cell Responses from Seronegative and Polymerase Chain Reaction-Negative Persons Exposed to HTLV-I

M. Nishimura, A.G. Kermode, M. Clerici, G.M. Shearer, J.A. Berzofsky, T. Uchiyama, S.Z. Wiktor, E. Pate, B. Maloney, A. Manns, …

Journal of Infectious Diseases, Vol.170(2), pp.334-338

1994

DOI: https://doi.org/10.1093/infdis/170.2.334

Files and links (1)

url

Link to Published Version *Subscription may be requiredView

Abstract

Human T lymphotropic virus type I (HTLV-I) is a human retrovirus etiologically linked to adult T-cell leukemiaand the progressive chronic neurologic disease HTLV-I-associated myelopathy/tropical spastic paraparesis. Described is a method that measures the production of interleukin-2 from HTLV-I synthetic peptide-stimulated peripheral blood lymphocytes (PBL) of HTLV-I-infected persons. The peptides correspond to immunogenic regions of the HTLV-I Env and Tax proteins. Significantly, this assay demonstrated T cell responses to these HTLV-I peptides from coded PBL samples in 7 of 19 HTLV-I-seronegative polymerase chain reaction-negative persons known to have been exposed to HTL V-I but in none of 16 matched controls without risk factors for exposure (P = .007). The implications of this finding are discussed.

Details

Title: Demonstration of Human T Lymphotropic Virus Type I (HTLV-I)-Specific T Cell Responses from Seronegative and Polymerase Chain Reaction-Negative Persons Exposed to HTLV-I
Authors/Creators: M. Nishimura (Author/Creator) - National Institute of Neurological Disorders and Stroke
A.G. Kermode (Author/Creator) - National Institute of Neurological Disorders and Stroke
M. Clerici (Author/Creator) - National Institute of Neurological Disorders and Stroke
G.M. Shearer (Author/Creator) - National Institute of Neurological Disorders and Stroke
J.A. Berzofsky (Author/Creator) - National Institute of Neurological Disorders and Stroke
T. Uchiyama (Author/Creator) - National Institute of Neurological Disorders and Stroke
S.Z. Wiktor (Author/Creator) - National Institute of Neurological Disorders and Stroke
E. Pate (Author/Creator) - National Institute of Neurological Disorders and Stroke
B. Maloney (Author/Creator) - National Institute of Neurological Disorders and Stroke
A. Manns (Author/Creator) - National Institute of Neurological Disorders and Stroke
W. Blattner (Author/Creator) - National Institute of Neurological Disorders and Stroke
S. Jacobson (Author/Creator) - National Institute of Neurological Disorders and Stroke
Publication Details: Journal of Infectious Diseases, Vol.170(2), pp.334-338
Publisher: Oxford University Press
Identifiers: 991005542374307891
Copyright: © 1994 Infectious Diseases Society of America
Murdoch Affiliation: Murdoch University
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

25 Record Views

11 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.66 HIV; 1.66.1464 HTLV-1/BLV Pathogenesis
Web Of Science research areas: Immunology; Infectious Diseases; Microbiology
ESI research areas: Immunology